Regeneron registers two new trials: prion disease gene therapy and HS/obesity combo drug

Regeneron Pharmaceuticals posted two new clinical trial registrations in September 2026, both listed as not yet recruiting.

• A Phase 1/2 open-label trial (NCT07832370) will test ALN-6457, also known as ALN-PRNP, in adults with symptomatic prion disease. The drug is designed to reduce the amount of prion protein made in the brain by targeting the genetic instructions cells use to produce the protein, with the goal of slowing or stopping disease progression.¹ The study plans to enroll 60 participants (estimated)¹ with an estimated primary completion date of 2031-02-27.
• A Phase 2 randomized, placebo-controlled trial (NCT07830329) will evaluate olatorepatide, also called HS-20094, a GLP-1/GIP receptor agonist, in adults with moderate to severe hidradenitis suppurativa who are overweight or obese. The trial aims to see whether the drug helps improve HS symptoms and quality of life and supports weight loss², with an estimated enrollment of 300 participants and a primary completion date of 2028-11-24.